D. Boral Capital lowered the firm’s price target on Immunic (IMUX) to $10 from $17 and keeps a Buy rating on the shares after the company priced an oversubscribed $65M underwritten public offering structured as a unit offering at $0.7499 per unit, with each unit comprising one pre-funded warrant, one Series A warrant, and one Series B warrant. While this capital raise is a near-term positive for operating runway, the structure of the deal, which includes pre-funded warrants and two classes of exercisable warrants, implies a potential for substantial dilution, bringing up to 260M new shares into play, which justifies a downward revision in valuation, the analyst tells investors.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMUX:
- Immunic announces pricing of $65M public offering
- Immunic Announces Public Offering to Fund Trials
- Immunic announces offering of warrants to purchase common stock
- Immunic price target lowered to $5 from $6 at B. Riley
- Buy Rating Affirmed for Immunic’s Vidofludimus Calcium Due to Promising Phase 2 Results and Strong MS Treatment Potential